Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Pharmaceuticals Canada (RPCI) has received Health Canada approval to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system.
Subscribe to our email newsletter
Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication).
RPCI, a wholly owned subsidiary of Ranbaxy Laboratories, sells and distributes generic prescription products in the Canadian healthcare system.
RPCI Canada president and general manager Paul Drake said the finished dosage form was developed, and will be manufactured within RLL’s Health Canada approved facilities located in India.
"We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," Drake added.